Breaks Categories: Stock Spotlights

FridayJun 06, 2025 2:00 pm

BioMedNewsBreaks — Why Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’

Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. INBS was featured in a recent article that reads, “By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings… The company’s vision is to redefine drug screening by removing the pain points of traditional testing methods, including biohazardous waste, privacy concerns, and long result turnaround times. With results in under 10 minutes and no need for gender-specific collectors or laboratory facilities, the system empowers…

Continue Reading

WednesdayJun 04, 2025 3:36 pm

BioMedNewsBreaks — Adageis Empowers Providers with Actionable Insights for Value-Based Care Success

Adageis, a growing healthcare technology company, offers a unique streamlined and AI-powered software solution designed to make the shift toward value-based care simpler for healthcare practices. “At the core of the company’s offering is the ProActive Care Platform, a patented, AI-centric engine that enables providers, health systems, ACOs, and CINs to identify and act on high-value opportunities within their existing operations,” reads a recent article. “What sets Adageis apart is ease of use, giving practices clear, actionable insights on where value lies, and how to pursue it while maintaining or improving quality of care.” To view the full article, visit…

Continue Reading

FridayMay 30, 2025 3:41 pm

BioMedNewsBreaks — Adageis’ AI-Powered Insights Aim to Improve Outcomes, Revenue Forecasting

Adageis, a forward-thinking healthcare technology company, has a comprehensive suite of AI-powered solutions aimed at providers shifting from fee-for-service to value-based care. “At the core of the company’s offering is its ProActive Care Platform, which combines predictive analytics with real-time data integration to improve both clinical and financial outcomes,” reads a recent article. “The platform’s Patented Risk Engine (‘PRE’) enables users to forecast revenue based on quality performance metrics and patient care patterns. For providers managing contracts that tie compensation to outcomes, these insights are increasingly important.” To view the full article, visit https://ibn.fm/Rfnx2 About Adageis Adageis is a healthcare…

Continue Reading

ThursdayMay 22, 2025 3:34 pm

BioMedNewsBreaks — Soligenix Inc.’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma (“CTCL”), a rare form of cancer that affects the skin. “Soligenix’s proprietary treatment, HyBryte(TM), is currently in clinical trials, and the latest results have shown promising efficacy in treating CTCL,” reads a recent article. “‘Following 18 weeks of treatment, 75% of patients achieved ‘Treatment Success,’ reinforcing HyBryte(TM) as a potentially safe and fast-acting therapy for this chronic and underserved cancer,’ the company reported. The study results suggest that the treatment may be highly effective in reducing…

Continue Reading

ThursdayMay 22, 2025 3:08 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer rates continue to rise, Calidi’s RTNova platform and tumor-specific virotherapy hold the promise of offering new hope to cancer patients, addressing the limitations of existing treatments, and potentially improving survival rates across multiple cancer types. The company’s ongoing research and deep commitment to scientific excellence position…

Continue Reading

ThursdayMay 15, 2025 3:35 pm

BioMedNewsBreaks — Adageis’ Fintech Platform Drives Smarter, More Profitable Healthcare

Adageis, a forward-thinking healthcare technology company, is empowering clinics and medical groups to succeed in the shift from fee-for-service to value-based care through its AI-powered platform. The company’s ProActive Care solution deciphers complex insurance contracts, integrates with leading EHR systems, and offers real-time analytics to help providers track revenue trends as well as their performance and profitability. Proprietary components of the platform, including the Value-Based Care Engine and Patented Risk Engine, identify care gaps and high-risk patients, enabling earlier interventions that enhance both clinical and financial performance. By developing targeted solutions, with a focus on smaller and independent practices, Adageis…

Continue Reading

ThursdayMay 15, 2025 2:47 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential to be the world’s first and only abuse deterrent patch platform for managing chronic pain. The company also deepened its collaboration with Kindeva Drug Delivery through an amended agreement focused on the development of Aversa(TM) Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl…

Continue Reading

FridayMay 09, 2025 2:54 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation. “Targeting tumors with a systemic virotherapy with a multimodal mechanism of action, which includes direct killing of the tumors and robust activation of antitumor immune responses, may revolutionize the way we approach cancer treatments,” said a Calidi spokesman. “We are excited to have shown…

Continue Reading

ThursdayMay 08, 2025 3:37 pm

BioMedNewsBreaks — Adageis’ AI-Powered Platform Empowers Smarter Billing, Better Care

Adageis, a healthcare technology company, is transforming how providers manage insurance payments with its AI-driven software platform, designed to enhance transparency, ensure reimbursement, and support the shift to value-based care. By offering real-time insights into expected payments, identifying reimbursement gaps, and evaluating performance, Adageis empowers clinics—especially smaller or new practices—to optimize revenue, negotiate better insurance contracts, and make informed financial decisions. The platform helps providers navigate complex insurance arrangements while improving profitability, quality, and a focus on patient care. With growing interest in the healthcare technology sector, Adageis stands out as a promising investment opportunity. To view the full article,…

Continue Reading

TuesdayApr 29, 2025 12:41 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel photodynamic therapy designed to treat early-stage cutaneous T-cell lymphoma (“CTCL”). Building on the success of a prior phase 3 trial, HyBryte(TM)—which uses synthetic hypericin activated by safe visible light—offers a potentially game-changing approach by providing a noninvasive, well-tolerated alternative that targets malignant T-cells with precision. With patient enrollment underway and interim analysis expected in early 2026, the study is designed to potentially meet the stringent requirements of regulatory agencies in order to strengthen the case for HyBryte(TM) as a commercially available…

Continue Reading